NCT04836520已完成2 期
Single-arm, Single-center, PhaseⅡ Clinical Study of SHR6390 Combined With Anastrozole for Preoperative Treatment of Hormone Receptor Positive and HER2 Negative Early or Locally Advanced Breast Cancer.
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年8月2日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Changes in Ki67 scores
研究概览
简要总结
The study is being conducted to assess effect of SHR6390 combined with anastrozole on proliferation of HR-positive HER2-negative breast cancer tumor cells before surgery.
详细描述
This is a single-arm, single-center, open-label Phase II clinical study. The purpose of this study was to evaluate the effect of SHR6390 combined with anastrozole on the proliferative activity of HR-positive HER2-negative breast cancer tumor cells before surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •1.Female subjects aged 18 to 75 years old, meet any of the following:
- •Both ovaries have been removed, or the age is ≥60 years old;
- •Age <60 years, natural post-menopausal state (defined as spontaneous menstrual cessation for at least 12 consecutive months without other pathological or physiological reasons), E2 and FSH are at postmenopausal levels;
- •Premenopausal or perimenopausal female subjects must be willing to receive LHRH agonist treatment during the study; 2.T2-T4cN0M0 invasive breast cancer (according to the AJCC 8th edition breast cancer clinical staging guidelines), the tumor must be surgically resectable, the measurable lesion conforms to the RECIST 1.1 standard, and the maximum diameter of the primary tumor has been evaluated by clinical or imaging evaluation ≥ 2cm; 3.Willing to accept biopsy; 4.Luminal A confirmed by immunohistochemistry, ER≥50% and PR≥50%; 5.HER2 negative, defined as immunohistochemical test 0/1+; or FISH test HER2/CEP17 ratio is less than 2.0 or HER2 gene copy number is less than 4; 6.Patients are suitable for neoadjuvant therapy and willing to accept (judged by the investigator); 7.ECOG performance status score 0 or 1; 8.The expected survival period is not less than 12 weeks; 9.Adequate function of major organs； 10.Voluntary participation in the study, signed informed consent, good compliance and willingness to cooperate with follow-up.
排除标准
- •Metastases confirmed by imaging or pathology, not including lymph node metastases in the ipsilateral and/or contralateral thoracic region or mediastinum;
- •Inflammatory breast cancer, bilateral breast cancer or DCIS, invasive breast cancer with multiple focal lesions;
- •Previous pathological diagnosis of HER2-positive breast cancer;
- •Suffering from gastrointestinal diseases such as intestinal obstruction, peptic ulcer or active bleeding, which affects the taking and absorption of drugs;
- •Previously treated with radiotherapy, chemotherapy, surgery (not including percutaneous puncture) or molecular targeted treatment;
- •Previously received any CDK4/6 inhibitor drug treatment;
- •Participation in any other clinical trials within 4 weeks of enrollment；
- •Concurrent use of any other Anti-cancer drugs；
- •Other malignancies within 5 years, except cured in-situ of uterine cervix carcinoma , skin basal cell carcinoma and squamous-cell carcinoma;
- •History of heart disease: (1) Arrhythmias requiring medical treatment or clinical significance, (2) Myocardial infarction, (3) Heart failure, (4)Any heart diseases that investigator believes not suitable for this study;
- •History of allergy or hypersensitivity to any of the study drugs or study drug components; history of immunodeficiency including HIV-positive, active hepatitis B/C, other acquired, congenital immunodeficiency disease or history of organ transplantation；
- •A clear history of neurological or mental disorders, including epilepsy or dementia；
- •Pregnant or breastfeeding women. Women of childbearing potential who have a positive pregnancy test or unwilling to use adequate contraception prior to enrollment and for the duration of study participation；
- •According to the investigator's judgment, there is a concomitant disease that seriously endangers the safety of subjects or affects the completion of the study (including but not limited to severe hypertension, severe diabetes, active infection, thyroid disease that cannot be controlled by drugs)；
- •Any condition which in the investigator's opinion makes the subjects unsuitable for the study participation.
研究组 & 干预措施
SHR6390+anatrozole
Experimental
Hormone receptor positive, HER2 negative participants will receive SHR6390 in combination with anatrozole before surgery.
干预措施: SHR6390+anatrozole (Drug)
结局指标
主要结局
Changes in Ki67 scores
时间窗: up to 5 months
Serial measures of Ki67 (%)
RCB (0-1) after surgery
时间窗: 5 months
Rate of Residual Cancer Burden 0-1
次要结局
- Objective response rate (ORR) evaluated by the investigator(16 weeks)
- tpCR(5 months)
- Safety will be assessed using NCI Common Terminology Criteria for Adverse Events v5.0 (CTCAE)(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.HER2-positive Breast CancerER-positive Breast CancerBreast CancerNCT04236310Ruijin Hospital37
尚未招募
2 期
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic CancerPancreatic CancerNCT05185869Ruijin Hospital58
已完成
1 期
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerAdvanced Breast CancerNCT03481998Jiangsu HengRui Medicine Co., Ltd.104
进行中（未招募）
3 期
Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeHormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast CancerNCT04842617Jiangsu HengRui Medicine Co., Ltd.5,274
已完成
1 期
A Phase I Clinical Study on SHR6390 in Healthy Chinese VolunteersHealthy VolunteersNCT05354336The Affiliated Hospital of Qingdao University36